Our Trovera® liquid biopsy tests provide actionable information about EGFR, KRAS, and BRAF mutations, often associated with common solid tumor cancers, to aid you in choosing the right treatment for the right patient at the right time.

EGFR Mutation Testing

EGFR (the gene that produces a protein called epidermal growth factor receptor) is abnormal or mutated, in about 10% of patients with non-small cell lung cancer (NSCLC) and in nearly 50% of lung cancers arising in those who have never smoked.

KRAS Mutation Testing

The KRAS gene is in the Ras family of oncogenes, which also includes two other genes: HRAS and NRAS. This gene provides instructions for making a protein called K-Ras that is involved primarily in regulating cell division.

BRAF Mutation Testing

The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell’s nucleus.


Noninvasive and
Convenient Testing

Our Trovera liquid biopsy tests enable physicians to use urine or blood as the sample type, allowing for easy and frequent assessment of mutational status without the need for invasive, more time consuming procedures. Urine is the epitome of a noninvasive, replenishable and convenient ctDNA source.

Ultra-Sensitive
Mutation Detection

Our proprietary Precision Cancer Monitoring® (PCM) technology enables industry-leading sensitivity with detection as low as 0.006%, or ten times greater than other currently available liquid biopsy methods. This sensitivity is the equivalent of detecting one cancer cell per 20,000 non-cancer cells.

Clinically Actionable,
Quantitative Results

We focus our Trovera® tests on mutations that are well documented in treatment guidelines and clinically actionable, helping physicians select from among the most appropriate therapies available. We provide quantitative test results so that physicians can track their patients’ tumor mutation levels and trends before, during and after treatment.

Clinically Actionable,
Quantitative Results

We focus our Trovera® tests on mutations that are well documented in treatment guidelines and clinically actionable, helping physicians select from among the most appropriate therapies available. We provide quantitative test results so that physicians can track their patients’ tumor mutation levels and trends before, during and after treatment.

Order a test

Interested in ordering a sample collection kit?